Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Given Consensus Rating of “Hold” by Analysts

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have earned an average rating of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $5.00.

Several equities research analysts have recently weighed in on CTXR shares. HC Wainwright reiterated a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday. Zacks Research upgraded shares of Citius Pharmaceuticals to a “hold” rating in a research report on Tuesday, May 19th. Wall Street Zen lowered Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, June 24th. Finally, Citigroup reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday.

Hedge Funds Weigh In On Citius Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new position in Citius Pharmaceuticals during the 2nd quarter valued at $32,000. NewEdge Advisors LLC bought a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at about $40,000. Asset Advisory Group Inc. purchased a new position in shares of Citius Pharmaceuticals during the fourth quarter valued at about $46,000. BlackRock Inc. bought a new position in Citius Pharmaceuticals in the second quarter worth about $42,000. Finally, Heights Capital Management Inc. purchased a new position in shares of Citius Pharmaceuticals in the 4th quarter valued at approximately $622,000. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Stock Performance

Shares of CTXR opened at $0.57 on Wednesday. The business has a 50-day moving average of $0.58 and a 200 day moving average of $0.69. Citius Pharmaceuticals has a fifty-two week low of $0.47 and a fifty-two week high of $2.19. The firm has a market cap of $15.70 million, a P/E ratio of -0.27 and a beta of 1.03.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. The business had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $5.46 million. As a group, research analysts predict that Citius Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.